Belite Bio announced the submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour, and Welfare for tinlarebant to treat Stargardt disease type 1 under the Sakigake Designation System. This filing coincides with the U.S. FDA acceptance of an NDA for the same indication, which carries a Prescription Drug User Fee Act target action date of February 12, 2027. If approved, tinlarebant would be the first treatment for Stargardt disease type 1 in Japan and potentially the first ophthalmology product to receive approval under the Sakigake pathway. The company's lead candidate has previously met primary endpoints in Phase 3 trials for this condition. Belite Bio is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for degenerative retinal diseases.

Belite Bio reported unaudited financial results for the second quarter ended June 30, 2026. The company holds $279.9 million in cash and equivalents alongside $500.1 million in investments. R&D expenses rose to $18.2 million from $11.0 million a year earlier, while SG&A increased to $16.7 million from $6.5 million due to team expansion and professional fees. The net loss widened to $28.4 million compared to $16.3 million in the prior-year period. A key corporate update is that the FDA accepted the New Drug Application for tinlarebant for Stargardt disease type 1 with Priority Review status, setting a PDUFA target action date of February 12, 2027. The company also presented additional positive secondary endpoint data from its Phase 3 DRAGON trial at the ASRS Annual Meeting. Belite Bio is a clinical-stage biotechnology company focused on developing novel therapeutics for degenerative retinal diseases.

On August 11, 2026, Belite Bio announced that the U.S. Food and Drug Administration accepted its New Drug Application for tinlarebant to treat Stargardt Disease Type 1 and granted it Priority Review designation. The FDA has set a Prescription Drug User Fee Act target action date of February 12, 2027. The application was based on Phase 3 DRAGON trial results showing a statistically significant 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo. If approved, tinlarebant would be the first-ever FDA-approved treatment for this rare inherited retinal disease affecting an estimated 53,000 people in the U.S. Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases.

Belite Bio, Inc. completed a rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tinlarebant. This drug is intended for the treatment of Stargardt Disease Type 1. Belite Bio, Inc. is a biotechnology company focused on developing therapies for retinal diseases.